Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1641-1660 of 1,738 trials

Prostate Cancer: Androgen Deprivation Therapy and PSMA

We are studying how androgen deprivation therapy affects the expression of a specific protein in metastatic prostate cancer. This research may help us understand treatment responses and disease progression better.

Metastatic Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Autoimmune Disease: CAR-Expressing NK Cell Therapy

We are testing a new therapy using engineered immune cells for people with active B-cell driven autoimmune diseases. The study aims to assess safety and effectiveness in conditions like lupus and scleroderma.

Systemic Lupus ErythematosusSystemic SclerosisIdiopathic Inflammatory MyopathySafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Type 1 Diabetes: Deferoxamine for Hypoxia Response

We are studying whether deferoxamine can improve how people with type 1 diabetes react to low oxygen levels. This trial will help us understand its potential benefits in managing diabetes.

Type 1 Diabetes>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesEndocrinologyInternal Medicine

Solid Tumors: MK-5684 Study

We are testing a new treatment, MK-5684, for people with certain solid tumors to see if it helps them live longer without disease progression. The study also evaluates its safety and effectiveness compared to standard care.

Breast CancerOvarian CancerEndometrial Cancer6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Rezafungin for Chronic Pulmonary Aspergillosis Treatment

We are studying whether rezafungin can effectively treat chronic pulmonary aspergillosis in adults with few treatment options. The trial will assess both the effectiveness and safety of this medication.

Chronic Pulmonary Aspergillosis6-12 monthsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPulmonology

Insomnia in Adolescents: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep in adolescents with psychiatric disorders and insomnia. We’ll also look at how these treatments affect overall well-being and daily functioning.

Psychiatric Disorders and Insomnia≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Metastatic Colorectal Cancer: New Diagnostic Test for Treatment Guidance

We are studying a new test to help doctors determine the best third-line therapy for patients with metastatic colorectal cancer. The goal is to see if this test provides accurate and reliable information for treatment decisions.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Metastatic Melanoma: V940 and Pembrolizumab Study

We are studying a new treatment combining V940 with pembrolizumab for people with metastatic melanoma. The aim is to see if this combination helps improve survival compared to a placebo.

Melanoma>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementOncology

Head and Neck Cancer: Ficerafusp Alfa with Pembrolizumab

We are studying whether ficerafusp alfa combined with pembrolizumab can effectively treat patients with recurrent or metastatic head and neck cancer. This trial aims to find the best dose and compare its effects to a placebo.

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Chronic Limb-Threatening Ischemia: Bone Marrow Cell Therapy

We are comparing a new treatment using your own bone marrow cells with standard care for diabetic patients with severe circulation problems. The goal is to see if this therapy improves tissue oxygen levels and overall health.

Diabetic Foot SyndromeLower Limb Ischemia6-12 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCardiologyEndocrinologyInternal MedicineOrthopedics and Traumatology

Knee Surgery: Testing SRSD107 for Blood Clot Prevention

We are studying whether SRSD107 can effectively prevent blood clots in adults undergoing knee replacement surgery. We will also assess how safe it is compared to the standard treatment, enoxaparin.

Venous Thromboembolism6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyOrthopedics and Traumatology

WSD0922-FU for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment for patients with advanced NSCLC who have a specific mutation and did not respond to prior therapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPulmonology

GSK4418959 for Solid Tumors: A New Treatment Approach

We are investigating the safety and early effectiveness of the DNA-repair inhibitor GSK4418959 in adults with specific solid tumors. This study looks at the drug alone and with other cancer treatments to see how well it works.

Colorectal Cancer3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Hidradenitis Suppurativa: Tibulizumab Study

We are evaluating the effects of tibulizumab on skin lesions and quality of life for adults with hidradenitis suppurativa. The study also looks at the safety and tolerability of this treatment.

Hidradenitis Suppurativa6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

Sickle Cell Disease: Tebapivat Study

We are investigating a new medication, tebapivat, to see if it helps improve anemia in people with sickle cell disease. The study will also look at its safety and effects on fatigue and pain.

Sickle Cell Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Metastatic Uveal Melanoma: Liver Radiotherapy with Tebentafusp

We are studying if adding liver-directed radiotherapy to the standard treatment helps patients with metastatic uveal melanoma live longer and stay on treatment longer. This trial also looks at how the body responds to the combination therapy.

Metastatic Uveal MelanomaEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Atopic Dermatitis: Long-term Study of APG777

We are examining the long-term safety and effectiveness of APG777 in patients with moderate-to-severe atopic dermatitis who have already used this treatment. The goal is to see how well it works over time and if it remains safe.

Atopic DermatitisEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Non-Small Cell Lung Cancer: BMS-986504 Treatment Study

We are evaluating a new medication for patients with advanced non-small cell lung cancer who have a specific genetic deletion. The study aims to understand how well it works and its safety compared to previous treatments.

Advanced or Metastatic Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Narcolepsy and Idiopathic Hypersomnia: ALKS 2680 Study

We are investigating the safety and tolerability of ALKS 2680 for people with narcolepsy and idiopathic hypersomnia. The study also looks at its effects on excessive daytime sleepiness and cataplexy.

Narcolepsy and Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Cystic Fibrosis: Nebulized Bacteriophage Treatment

We are studying a new nebulized treatment for adults with cystic fibrosis and chronic Pseudomonas lung infection. The goal is to see if it helps reduce the infection and improve lung function and quality of life.

Cystic Fibrosis≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology